Economic evaluation of everolimus plus exemestane versus bevacizumab plus paclitaxel and bevacizumab plus capecitabine for the management of postmenopausal women with ER+ breast cancer. Conference Paper uri icon

authors

  • Panagiotakos, Demosthenes
  • Kourlaba, Georgia
  • Rapti, Vasiliki
  • Alexopoulos, Athanasios
  • Relakis, John
  • Koumakis, Georgios
  • Chatzikou, Magdalini
  • Maniadakis, Nikolaos
  • Georgoulias, Vassilis

publication date

  • May 20, 2014